HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Breast Cancer Res Treat
; 196(3): 571-581, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-36280642
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Límite:
Female
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article